Search Results - Raúl Márquez Vázquez
- Showing 1 - 2 results of 2
-
1
Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trial by Víctor Moreno, Maria-Pilar Barretina-Ginesta, Jesús García-Donás, Gordon C. Jayson, Patricia Roxburgh, Raúl Márquez Vázquez, Agnieszka Michael, Antonio Antón-Torres, R. H. Brown, David Krige, Brian Champion, Iain A. McNeish
Published 2021Artigo -
2
Profiling the gut and oral microbiota of hormone receptor-positive, HER2-negative metastatic breast cancer patients receiving pembrolizumab and eribulin by Nancy M. Y. Teng, Andrea Malfettone, Matthew J. Dalby, Raymond Kiu, David Seki, Tim Robinson, María Gión, Begoña Bermejo, José Manuel Pérez-García, Aleix Prat, Raúl Márquez Vázquez, Antonio Llombart–Cussac, Giuseppe Curigliano, Peter Schmid, Romualdo Barroso‐Sousa, Mario Mancino, Eileen Shimizu, José Rodríguez-Morató, Leonardo Mina, Lindsay J. Hall, Stephen D. Robinson, Javier Cortés
Published 2024Artigo
Search Tools:
Related Subjects
Internal medicine
Medicine
Adverse effect
Antibiotics
Bacteroides fragilis
Biology
Cancer
Chemotherapy
Clinical endpoint
Clinical trial
Discontinuation
Dosing
Febrile neutropenia
Gut flora
Immunology
Leukopenia
Loading dose
Microbiology
Neutropenia
Oncology
Ovarian cancer
Paclitaxel
Phases of clinical research
Response Evaluation Criteria in Solid Tumors
Saliva